Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $19.00 by Analysts at Scotiabank
Sage Therapeutics (NASDAQ:SAGE – Free Report) had its price objective reduced by Scotiabank from $34.00 to $19.00 in a research note published on Thursday morning, Benzinga reports. They currently have a sector outperform rating on the biopharmaceutical company’s stock. Several other research firms also recently weighed in on SAGE. Bank of America downgraded Sage Therapeutics […]